Molecular Biomarkers of Neovascular Age-Related Macular Degeneration With Incomplete Response to Anti-Vascular Endothelial Growth Factor Treatment.
Inflammation
Soluble vascular cell adhesion molecule-1 (sVCAM-1)
age-related macular degeneration (AMD)
angiogenic factors
bioactive interleukin-12 (IL-12p40)
hepatocyte growth factor (HGF)
interleukin-6 (IL-6)
plasminogen ctivator inhibitor type 1 (PAI-1)
Journal
Frontiers in pharmacology
ISSN: 1663-9812
Titre abrégé: Front Pharmacol
Pays: Switzerland
ID NLM: 101548923
Informations de publication
Date de publication:
2020
2020
Historique:
received:
14
08
2020
accepted:
19
11
2020
entrez:
15
1
2021
pubmed:
16
1
2021
medline:
16
1
2021
Statut:
epublish
Résumé
The standard treatment for neovascular age-related macular degeneration (nAMD) consists of intravitreal anti-vascular endothelial growth factors (VEGF). However, for some patients, even maximal anti-VEGF treatment does not entirely suppress exudative activity. The goal of this study was to identify molecular biomarkers in nAMD with incomplete response to anti-VEGF treatment. Aqueous humor (AH) samples were collected from three groups of patients: 17 patients with nAMD responding incompletely to anti-VEGF (18 eyes), 17 patients affected by nAMD with normal treatment response (21 eyes), and 16 control patients without any retinopathy (16 eyes). Proteomic and multiplex analyses were performed on these samples. Proteomic analyses showed that nAMD patients with incomplete anti-VEGF response displayed an increased inflammatory response, complement activation, cytolysis, protein-lipid complex, and vasculature development pathways. Multiplex analyses revealed a significant increase of soluble vascular cell adhesion molecule-1 (sVCAM-1) [
Identifiants
pubmed: 33447243
doi: 10.3389/fphar.2020.594087
pii: 594087
pmc: PMC7802772
doi:
Types de publication
Journal Article
Langues
eng
Pagination
594087Informations de copyright
Copyright © 2020 Mantel, Borgo, Guidotti, Forestier, Kirsch, Derradji, Waridel, Burdet, Mehl, Schweizer and Roduit.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
N Engl J Med. 2006 Oct 5;355(14):1419-31
pubmed: 17021318
Am J Pathol. 2000 Jul;157(1):135-44
pubmed: 10880384
Arterioscler Thromb Vasc Biol. 2006 Oct;26(10):2407-13
pubmed: 16902162
Nat Methods. 2014 Mar;11(3):319-24
pubmed: 24487582
J Proteome Res. 2011 Apr 1;10(4):1794-805
pubmed: 21254760
Br J Ophthalmol. 2015 Jun;99(6):723-6
pubmed: 25425713
N Engl J Med. 2006 Oct 5;355(14):1432-44
pubmed: 17021319
PLoS Pathog. 2008 Sep 19;4(9):e1000158
pubmed: 18802456
Mol Cell Proteomics. 2014 Sep;13(9):2513-26
pubmed: 24942700
Nat Methods. 2016 Sep;13(9):731-40
pubmed: 27348712
Drug Des Devel Ther. 2016 Jun 02;10:1857-67
pubmed: 27330279
JAMA Ophthalmol. 2014 Apr 1;132(4):446-55
pubmed: 24481424
Graefes Arch Clin Exp Ophthalmol. 2013 Dec;251(12):2697-704
pubmed: 23665864
Arch Ophthalmol. 2005 Jun;123(6):774-82
pubmed: 15955978
Eye (Lond). 2018 Jun;32(6):1010-1020
pubmed: 29398697
OMICS. 2012 May;16(5):284-7
pubmed: 22455463
Int Ophthalmol Clin. 2015 Summer;55(3):63-78
pubmed: 26035762
J Ophthalmol. 2014;2014:502174
pubmed: 25110587
Acta Ophthalmol. 2012 Aug;90(5):e381-8
pubmed: 22490043
Nat Biotechnol. 2008 Dec;26(12):1367-72
pubmed: 19029910
Invest Ophthalmol Vis Sci. 2000 Jun;41(7):1885-93
pubmed: 10845613
Ophthalmology. 2012 Dec;119(12):2537-48
pubmed: 23084240
Clin Ophthalmol. 2018 Sep 26;12:1877-1885
pubmed: 30310267
Br J Ophthalmol. 2014 Sep;98(9):1192-6
pubmed: 24729031
Arch Ophthalmol. 2010 Oct;128(10):1281-6
pubmed: 20937997
Prog Retin Eye Res. 2016 Sep;54:64-102
pubmed: 27156982
Invest Ophthalmol Vis Sci. 2018 Aug 1;59(10):4106
pubmed: 30098197
Sci Rep. 2018 Jan 18;8(1):1098
pubmed: 29348424
Ophthalmol Retina. 2018 Jan;2(1):31-37
pubmed: 29376143
N Engl J Med. 2011 May 19;364(20):1897-908
pubmed: 21526923
Mol Vis. 2016 Apr 22;22:352-61
pubmed: 27122966
Nature. 2011 May 19;473(7347):337-42
pubmed: 21593866
Front Aging Neurosci. 2019 Oct 22;11:286
pubmed: 31695606
Ophthalmol Retina. 2020 Dec;4(12):1138-1145
pubmed: 31937473
FASEB J. 2001 Apr;15(6):1021-7
pubmed: 11292663
Br J Ophthalmol. 2011 Dec;95(12):1631-7
pubmed: 21546514
Invest Ophthalmol Vis Sci. 2019 Jan 2;60(1):202-208
pubmed: 30644965
Mol Cell Proteomics. 2014 Jan;13(1):339-47
pubmed: 24143002
Cell Signal. 2018 Apr;44:118-126
pubmed: 29339086